Brain 11 C-ITMM PET to longitudinally assess type 1 metabotropic glutamate receptor availability in Alzheimer's disease.
J Neuroimaging
; 31(5): 864-868, 2021 09.
Article
en En
| MEDLINE
| ID: mdl-34143915
ABSTRACT
BACKGROUND AND PURPOSE:
Little evidence exists on the role of type 1 metabotropic glutamate receptor (mGluR1) in the pathophysiology of Alzheimer's disease (AD), although mGluR1 may be involved in the regulation of neuronal excitability and synaptic plasticity. We have recently reported that mGluR1 availability in the early stage of AD is equivalent to that in healthy subjects. This study aimed to address whether mGluR1 availability changes with the progression of AD.METHODS:
Eight patients with AD (79.1 ± 4.6 years) underwent a total of two positron emission tomography (PET) examinations using the mGluR1 radioligand during the early-to-middle stages of AD. The mean interval was 2.8 years. Volumes-of-interest were placed on the frontal, parietal, and temporal cortices, hippocampus, anterior and posterior lobes, and vermis in the cerebellum. The binding potential (BPND ) was calculated to estimate mGluR1 availability, applying partial volume correction to the BPND values.RESULTS:
No significant difference was observed in BPND values between the first and second PET examinations in the frontal cortex (p = 0.94), parietal cortex (p = 0.67), temporal cortex (p = 0.20), hippocampus (p = 0.17), anterior lobe (p = 0.73), posterior lobe (p = 0.21), and vermis (p = 0.22).CONCLUSION:
This study suggests that mGluR1 availability is unchanged in the follow-up period of a few years during the early-to-middle stages of AD.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Receptores de Glutamato Metabotrópico
/
Enfermedad de Alzheimer
Límite:
Humans
Idioma:
En
Revista:
J Neuroimaging
Asunto de la revista:
DIAGNOSTICO POR IMAGEM
/
NEUROLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Japón